Quince Therapeutics, Inc. (QNCX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Quince Therapeutics, Inc. (QNCX) Bundle
As an investor or analyst, this [Symbol] DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from Quince Therapeutics, Inc. (QNCX), you can adjust forecasts and immediately observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -39.0 | -78.6 | -90.0 | -52.0 | -31.3 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .2 | .3 | .3 | .2 | .3 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -39.2 | -78.9 | -90.3 | -52.2 | -31.6 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 99.9 | 133.8 | 106.8 | 90.2 | 75.1 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | 1.0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | 2.2 | 2.3 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 3.1 | 3.6 | 4.9 | .6 | 2.0 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.1 | -.1 | -.2 | -.1 | -.2 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 | 0.62377 |
EBITAT | -39.0 | -78.9 | -89.7 | -51.9 | -31.4 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -35.8 | -78.1 | -90.4 | -56.2 | -28.5 | -1.0 | .0 | .0 | .0 | .0 |
WACC, % | 7.27 | 7.27 | 7.26 | 7.26 | 7.26 | 7.27 | 7.27 | 7.27 | 7.27 | 7.27 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -7 | |||||||||
Equity Value | 6 | |||||||||
Diluted Shares Outstanding, MM | 37 | |||||||||
Equity Value Per Share | 0.16 |
What You Will Receive
- Comprehensive Financial Model: Quince Therapeutics' actual data facilitates accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, discount rates, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive Data: Quince Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe Quince Therapeutics’ intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based QNCX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Quince Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial decisions.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novice and experienced users.
- Customizable Inputs: Tailor assumptions to suit your specific analysis needs.
- Real-Time Feedback: Observe immediate updates to Quince Therapeutics’ valuation as you adjust the parameters.
- Preloaded Data: Comes with Quince Therapeutics’ actual financial information for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts for making educated choices.
Who Should Use Quince Therapeutics, Inc. (QNCX)?
- Healthcare Investors: Make informed decisions with a reliable analysis of therapeutic innovations.
- Biotech Analysts: Streamline your research with comprehensive data on drug development and market potential.
- Consultants: Efficiently modify reports and presentations tailored to client needs in the biotech sector.
- Medical Professionals: Enhance your knowledge of cutting-edge therapies and their implications for patient care.
- Students and Educators: Utilize as a resource for understanding biotechnology and pharmaceutical industry dynamics.
What the Template Contains
- Historical Data: Includes Quince Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Quince Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Quince Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.